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a b s t r a c t
The objective of this study was to develop a high-fidelity prototype for delivering multi-gene sequencing
panel (GS) reports to clinicians that simulates the user experience of a final application. The delivery and
use of GS reports can occur within complex and high-paced healthcare environments. We employ a usercentered software design approach in a focus group setting in order to facilitate gathering rich contextual
information from a diverse group of stakeholders potentially impacted by the delivery of GS reports relevant to two precision medicine programs at the University of Maryland Medical Center. Responses from
focus group sessions were transcribed, coded and analyzed by two team members. Notification mechanisms and information resources preferred by participants from our first phase of focus groups were
incorporated into scenarios and the design of a software prototype for delivering GS reports. The goal
of our second phase of focus group, to gain input on the prototype software design, was accomplished
through conducting task walkthroughs with GS reporting scenarios. Preferences for notification, content
and consultation from genetics specialists appeared to depend upon familiarity with scenarios for ordering and delivering GS reports. Despite familiarity with some aspects of the scenarios we proposed, many
of our participants agreed that they would likely seek consultation from a genetics specialist after viewing the test reports. In addition, participants offered design and content recommendations. Findings illustrated a need to support customized notification approaches, user-specific information, and access to
genetics specialists with GS reports. These design principles can be incorporated into software applications that deliver GS reports. Our user-centered approach to conduct this assessment and the specific
input we received from clinicians may also be relevant to others working on similar projects.
Ó 2016 Elsevier Inc. All rights reserved.

1. Introduction
⇑ Corresponding author at: Department of Medicine, Divisions of General Internal
Medicine and Health Sciences Informatics, Johns Hopkins University School of
Medicine, 2024 East Monument Street, Suite 1-200, Baltimore, MD 21205, United
States.
E-mail address: overby@jhu.edu (C.L. Overby).
http://dx.doi.org/10.1016/j.jbi.2016.07.014
1532-0464/Ó 2016 Elsevier Inc. All rights reserved.

Customizing healthcare based on each person’s unique genetic
makeup could enable an era of precision medicine that would
improve prevention, diagnosis and treatment for many types of
health conditions. Routine precision medicine is rapidly approaching due to increased use of whole genome, whole exome, and other
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types of multi-gene next generation sequencing panels, hereafter
referred to as genomic sequencing (GS). Results from GS will be
used more often as cost goes down and evidence of clinical utility
increases [1,2]. With the overwhelming amounts of data that can
be generated from GS, the laborious task of manually prioritizing
clinically significant results often falls to clinical and laboratory
geneticists [3]. With the anticipated increase in the use of GS, manual review of genetic data by clinicians, however, is not scalable.
We believe that developing computerized tools to help nongenetics experts make sense of GS results will greatly increase
the likelihood of achieving the vision of successful use of these
data.
The healthcare environment in which such computerized tools
might be deployed can be complex and high-paced. Thus, there is a
need to use a design methodology that aims to support the current
way of working. The primary objective of this study was to develop
a high-fidelity prototype for delivering GS reports to clinicians that
simulates the user experience of a final application. Target stakeholders were clinicians involved in two University of Maryland
Program for Personalized and Genomic Medicine (PPGM) initiatives that are exemplary use cases for precision medicine programs
more broadly. These initiatives are the Translational Pharmacogenetics Program (TPP) and the Personalized Diabetes Medicine Program (PDMP). The TPP project aims to use a patient’s CYP2C19
genotype results to tailor antiplatelet therapy after a cardiac stent
has been placed [4]. The PDMP is designed to implement, disseminate and evaluate an approach to identifying and genomically
diagnosing highly penetrant genetic forms of diabetes. The goal
for PDMP is to enable personalized treatment for better and potentially less invasive glucose control, prognosis, and assessment of
familial risk for patients [5,6].
We employed a user-centered software design approach in a
focus group setting in order to facilitate gathering rich contextual
information with a diverse group of stakeholders potentially
impacted by the delivery of GS reports relevant to the TPP and
PDMP projects. We completed two studies: The goal for the first
study (phase 1) was to understand current genetic and laboratory
testing processes for documenting results, notifying clinicians of
those results, and viewing the results. Findings from the first study
were used to propose the design of software, which we called the
Genomic Medicine Assistant (GMA), for delivering GS reports to
clinicians. In particular, we proposed a design that would potentially mitigate issues with the reporting and notification processes
we identified in phase 1. The goal for the second study (phase 2)
was to gather feedback on a proposed design of the GMA software
including preferences for interactions with, content contained in
and the perceived usability of the design.

2. Background
Much of the research surrounding the delivery of individual GS
results to date has been regarding the ethical, legal and social
implications for communicating findings to patients [7–9]. Indeed,
GS technology is not mature and appropriate in all clinical scenarios and there is the potential for cascade effects (i.e., a chain of
events initiated by an unexpected result leading to unnecessary
additional testing or treatments) [10–13]. We are now seeing guidance for clinicians ordering, interpreting, and communicating GS
with their patients [13,14], as well as clinical laboratories supporting the ordering of GS and delivery of reports that include results
that are both clinically actionable and directly relevant to the
patients’ indication. While there are some studies exploring the
potential for GS to replace traditional tests in terms of sensitivity,
specificity and completeness [15], there are few studies to date
investigating technologies for delivering GS reports under this

new paradigm. One group has developed a web-based platform
to automatically generate a clinical report, based on pre-defined
templates, from raw assay results or specified diplotypes [16].
Their framework has potential to help provide consistent and
reproducible reporting while also saving time by calculating diplotypes and assembling report content. Our work adds to this emerging literature by taking a user-centered design approach to explore
a range of scenarios for software generating reports from GS for use
by clinicians.
Related to our goal to investigate preferences for content contained in the proposed design of software are studies of the information needs of clinicians when interpreting GS. These studies
serve as the groundwork to inform the design of software tools
[17,18]. While most of these studies have focused on genetic counselors’ information needs, some findings may be generalized to
other clinicians. Genetic counselors have expertise when reviewing
GS reports; therefore, information that they deem necessary
should be emphasized when non-genetic expert clinicians are
reviewing GS reports. For example, a study surveying genetic counselors showed that there is a perceived lack of information on the
classification system for variants of unknown significance (VUS)
included in laboratory reports, highlighting a need for improved
GS reports to provide transparency [18]. That study also found that
genetic counselors wanted more information, such as patient information, in reports to help contextualize VUS results [18]. We
believe this need for more information about the patient within
laboratory reports can be generalized to other types of clinicians
in order to make patient-specific recommendations. This belief is
supported by findings of others indicating that clinicians desire
information available to discuss with the patient [19]. Another
study of interviews with genetic counselors identified specific
information needs for risk communication [17]. Information needs
described in that study include clinical patient characteristics,
social and cognitive patient characteristics, and patient motivation
and goals for the genetic counseling session. Those needs may also
generalize to non-genetics experts communicating GS results to
patients more broadly, and thus were considered with findings
from phase 1 studies in our proposed software design.
While there exist tools and resources for clinical laboratory professionals interpreting and reporting genetic test results, the
design and purpose of these tools varies. One web-based application, SeqReporter, has been developed for clinical molecular laboratory use for next-generation sequencing data analysis [20].
That tool is an automated web-based application for GS result classification. While it was designed to optimize laboratory reporting,
it did not support the anticipated information needs of nongenetics expert clinical end users. While the published information
provides a starting point, our work gathers additional end-user
input on preferences for interactions with, content contained in
and the perceived usability of the software design by nongenetics clinician experts.
2.1. Methodological background
In order to gather input on the proposed design of software, we
used a task-centered system design (TCSD) protocol in a focus
group setting. Other studies have used similar task-centered
approaches to investigate the usability of genetic data interpretation software. For example, Shyr et al. administered surveys, conducted interviews and performed cognitive task analyses to
assess the usability of a clinical exome analysis software [21]. In
another study a think-aloud, graded-task protocol was used to
evaluate the GeneInsight Suite. That study highlighted a need to
provide the most current genetic information [22]. The graded task
protocol facilitated identifying design improvements that could be
easily made and determining larger issues with how the interface
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was interpreted by end-users. While our goals to gather input on
the design of software were similar, in our modified TCSD protocol,
we did not have participants grade each task they completed.
Rather, by conducting our study in a focus group setting, we
allowed for open discussion about proposed software design features in order to gather feedback on specific clinical contexts in
which those features would be most useful.
In proposing software design characteristics, we explored the
inclusion of features that might be supported by existing clinical
system vendors. These included alert messages, and an HL7 standard, the ‘‘Infobutton Standard” [23,24]. The use of infobuttons in
electronic health records (EHRs) is an important method for delivering the most current healthcare information to clinicians at the
point-of-care. The technology lends itself to use with GS reports,
as treatment guidelines and recommendations associated with
genetic variation are ever-improving [25]. Linking to those
resources from infobuttons could provide a mechanism to communicate genomic data and clinical decision support [26]. One study
piloted a pharmacogenomic-based prescribing alert to examine
the clinical impact of embedding infobuttons within an EHR alert
[27]. That study offered improvements to make the infobutton content more useful and increase clinician trust in the alert. Findings
from those studies reinforced our decision to include alert messages and infobuttons in the proposed design of software capable
of providing clinicians with important, current information with
GS results.
3. Materials and methods
3.1. Recruitment approach
Our two-phase study was conducted within a focus group setting. We sent emails to individuals influenced by the two precision
medicine projects at the University of Maryland School of
Medicine. These included 14 TPP/PDMP research team members
(clinical research coordinators, genetic counselors, laboratory professionals), 17 PDMP clinicians (endocrinology fellows, nurse practitioners, diabetes educators), and 34 TPP clinicians (cardiology
fellows, nurse practitioners, clinical pharmacists). The email was
sent with an information sheet describing the goals of the project.
Two weeks later, a second email was sent to the same pool of
potential participants asking for their participation again. A third
email was sent out to interested participants to schedule a focus
group. Interested participants were contacted a fourth and final
time to confirm the date and time of the focus group. A $100 gift
card was given to participants. Participants in phase 2 were
recruited in the same fashion and from the same pool of PDMP
and TPP clinicians as in phase 1. Those who participated in phase
1 were allowed to participate in phase 2. This study was reviewed
and judged by the University of Maryland Institutional Review
board (IRB) as non-human subjects research (HP-00061346). At
the start of each focus group, participants were given a participant
information sheet. This sheet captured the participant’s involvement in TPP and PDMP projects, years of experience in their profession, gender, and their choice to be contacted, or not, for future
focus groups.
3.2. Phase 1 data collection and analysis
In phase 1, three focus groups were conducted in order to
examine existing and anticipated genetic testing processes among
two precision medicine projects (TPP and PDMP). Our focus group
protocol was organized into three topics about genetic test results:
laboratory documentation of genetic test results, making genetic
test results available to view in the EHR, and notifying the clinician
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about genetic test results. For each topic, open-ended questions
(e.g., ‘‘what is your overall opinion of how genetic test results
should be documented by the testing lab?”) elicited general information followed by more specific questions and probes (e.g., ‘‘what
kinds of information do you think should or shouldn’t be in the
report?” ‘‘when would you want to access information you just
mentioned?”). A moderator and note taker were present at all
focus groups, each of which lasted 90–120 min. Focus group discussions regarding PDMP were modified to cover laboratory test
processes more generally given that data collection occurred prior
to the start of genetic testing for that project. Sessions were audio
recorded, transcribed, and analyzed with the aid of Dedoose, a
qualitative research analysis software [28].
Two coders (EC, CO) mapped statements made by study participants to terminology common to user experience and design, and
to organizational and business process modeling heuristics. Our
assessment of user experience in phase 1 was focused on usability
(effectiveness, efficiency and satisfaction) and design (missing
functionality, problems and proposed solutions, and desired features). Similar to another study of the usability of clinical systems
[29], we also captured ‘positive’ and ‘negative’ quotes. Positive
quotes allowed us to identify features that satisfied the needs of
clinicians and negative quotes allowed us to identify possible features to improve the use clinical systems for genetic testing processes. Mappings of statements to usability codes facilitated
determining perceived issues with the use of current clinical systems for genetic testing processes and proposed solutions acceptable by a range of stakeholders to address those issues. Mappings
of statements to organizational and business process modeling
heuristics facilitated determining existing and anticipated genetic
testing processes for documenting, viewing, and notifying individuals about genetic test results (Appendix B).
We completed two analyses of data collected in phase 1. First,
we analyzed the data to understand genetic testing processes of
TPP specifically. Findings from that analysis is described elsewhere
[30] and is summarized in the following section. Second, we analyzed phase 1 data in order to define scenarios and GMA design
requirements. Methods and results from that analysis are
described in this manuscript.

3.2.1. Summary of methods and findings from previous work analyzing
translational pharmacogenetics program genetic testing processes
The coding team analyzed data from two focus groups (TPP/
PDMP research team members and TPP-related clinicians) in order
to document TPP genetic testing processes at the time, and to propose more streamlined processes enabled by technology. With
information gained from focus groups, we documented TPP genetic
testing processes using a Business Process Model and Notation
(BPMN) model [30]. We also performed member checking to verify
the accuracy of our model. In summary, findings indicated a reliance on TPP research team members to complete tasks that were
labor-intensive and potentially error-prone. Findings also indicated insufficient support and resources to assist clinicians in
treatment decisions with the lab report alone. At the time, important information for making treatment decisions were provided by
the TPP research team in the form of a letter, separate from the lab
report itself. Specific recommendations to enhance TPP genetic
testing processes included reducing the reliance on the TPP
research team by establishing a Laboratory Information Management System (LIMS) for genetic test results that is capable of communicating with the EHR, and the implementation of clinical
decision support (CDS). CDS implementation could also provide a
mechanism to improve access to information for clinicians to make
treatment decisions.
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3.2.2. Assessing desired characteristics for precision medicine scenarios
and genomic medicine assistant design
We drew from data collected for two focus groups (TPP-related
clinicians and PDMP-related clinicians) to provide evidence for scenario and software design choices. Scenarios were designed to be
relevant to TPP and PDMP projects and validated with project advisory committee members. Committee members consisted of
experts in clinical genomics, clinical vocabulary standards and clinical decision support implementation in commercial EHRs (Appendix A). After scenario validation, we designed project-specific
‘‘storybook packets” that included two scenarios, each of which
had associated tasks for accessing GS reports, mockups of those
reports and information resources viewed using GMA. Those notification methods found to be acceptable by phase 1 study participants were described in both storybook packets. One team
member (EC) proposed initial GMA design mockups informed by
participant recommendations from phase 1 focus groups, the literature describing laboratory report design principles [31], and
model laboratory reports. The packets underwent multiple rounds
revision based upon feedback from the project team prior to
finalizing.
3.3. Phase 2 data collection and analysis
In phase 2, a modified task-centered system design (TCSD) protocol was applied in a focus group setting in order to gather feedback from clinicians on a proposed design of the GMA software.
Traditional TCSD involves four main phases: (a) identification of
tasks, (b) user-centered requirements analysis, (c) design through
use of scenarios or storybooks, and (d) evaluation of design using
walkthrough analyses [32]. In this study we leverage our understanding of preferences for genetic testing processes from phase
1 analyses in order to complete TCSD phases a–c. TPP and PDMP
clinicians were each asked to complete task walkthroughs involving two clinical scenarios where GS was performed (see Appendix
A for ‘‘Scenarios relevant to the Translational Pharmacogenomics
Project” and for ‘‘Scenarios relevant to the Personalized Diabetes
Medicine Program”).
3.3.1. Administering storybook packets for task walkthroughs with
clinicians
In phase 2, storybook packets were administered to study participants within a focus group setting. A moderator and note taker
were present at both focus groups, each of which lasted 90–
120 min. Focus groups were split into two parts, with no discussion
during the first part of the study. Participants were first asked to
spend 15–20 min reviewing and writing down comments or questions about each task/screen presented in the storybook packet. For
the second part, the moderator led a discussion of each task as a
group. The moderator facilitated discussion through the use of
probes (e.g., ‘‘Is this alert message informative?”) corresponding
to each task (e.g., ‘‘Clinician views alert message”). Sessions were
audio recorded, transcribed, and analyzed with the aid of Dedoose,
qualitative research analysis software [28].
3.3.2. Analysis of clinician perceptions of tasks and screen mockups
Two coders (EC, MB) mapped statements made by study participants to terminology common to user experience and design, processes for viewing and using the GMA, characteristics of the GMA
design (see Appendix C. Genomic Medicine Assistant Demo
Multi-Gene Panel Laboratory Reports), and roles for different
stakeholders (e.g., patient, lab professional, ordering physician,
genetic counselor). Our assessment of user experience was broader
in phase 1 than in phase 2 with the addition of codes for content
and usefulness added to our codebook. Codes for usability and
design remained. Codes for organizational and business processes

from phase 1 were replaced by a single code to capture processes
for viewing and using the GMA. Mappings of statements to codes
facilitated identifying preferences for and issues with proposed
design features and areas for which there was agreement or disagreement among focus group participants.
3.3.3. Analysis to characterize study participant views using system
usability scale survey
In order to characterize the views of our study participants, we
used the System Usability Scale (SUS) survey [33]. The SUS has
become a standard of usability measurement [34]. While other
usability evaluation surveys exist [35,36], the SUS is among the
most broadly used and has a number of advantages including its
ease of use with only 10 items rated on a 5-point scale; its comprehensibility given a resultant score ranging from 0 to 100; and it is
‘‘technology agnostic” [33,37]. Participants are asked to score each
item on a scale of one to five that range from Strongly Disagree to
Strongly Agree. Scores were interpreted and analyzed using Sauro’s
method (30). For each odd numbered item, one was subtracted
from the user response. For each even numbered item, the user
response was subtracted from five. Each user’s responses were
added up and multiplied by 2.5 to convert the range of values to
0–100. A score of 68 is an average usability score. A score above
68 would be considered above average, a score below 68 is considered below average. Scores were then converted to their percentile
rank [33].
4. Results
4.1. Study population
Phase 1 focus groups (three totals) were conducted between
December 2014 and February 2015. Phase 2 focus groups with clinicians (two totals) were conducted in May 2015 at UMMC. Each
focus group had a total of four participants (Table 1). With the
exception of one focus group conducted during phase 1 with
TPP/PDMP research team members, all focus groups included 1–2
nurse practitioners and 1–3 physicians. 6 clinicians (nurse practitioners and physicians) participated in both phases 1 and 2.
4.2. Phase 1 results: validated scenarios and proposed software design
The phase 1 analysis uncovered several desired characteristics
for scenarios and for the design of software to support processes

Table 1
Demographic Information collected about focus group participants: Gender, specialty,
years of experience.
Characteristics

N (%)

Gender
Female
Male

13 (65)
7 (35)

Study
Study 1
Study 2

12 (60)
8 (40)

Profession
Clinical Pharmacist
Physician (Fellow)
Nurse practitioner
TPP/PDMP research team (clinical research coordinators)
TPP/PDMP research team (laboratory professionals)

1 (5)
13 (65)
2 (10)
3 (15)
1 (5)

Clinical specialty
Cardiology
Endocrinology
NA

8 (40)
8 (40)
4 (20)

Years of experience (mean, range)

6.7, 1–35
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for documenting, viewing, and being notified of genetic and laboratory test results.
4.2.1. Feedback from clinicians informing genomic medicine assistant
design
Preferences for documenting and viewing genetic test results
informed the design of the GMA software. Specific clinical preferences for report documentation included embedding recommendations for the course of treatment based on the patient’s results.
This design choice was based primarily upon discussions occurring
in the TPP focus group session. The goal for this would be to reduce
the number of steps required for clinicians to review recommendations for using test results. At the time, recommendations were
provided to clinicians primarily within a letter sent by the study
team.
TPP and PDMP clinicians had similar preferences for viewing
test results. Given that multiple variants in a single gene or multiple genes may be presented in a single report, participants
expressed a desire for data to be organized by degree of urgency
and clinical significance. We proposed addressing this issue by
proposing the use of a multiple tabs to separate essential and
nonessential information in the proposed software design. We also
incorporated a specific recommendation of the TPP clinicians to
use to allow for quick review of the report (e.g., use of the color
red to indicate high urgency).
Decisions regarding the organization of content were also
informed by model laboratory reports and recommendations from
the literature [31]. Many features are generalizable across scenarios and are described in Table 3. Potentially generalizable content
and content sections are also illustrated in Fig. 1. Given differences
in the availability of information resources, the inclusion or exclusion of infobuttons varied slightly between scenarios.
Focus group participants also reported need for sufficient information to help non-specialist clinicians explain test results to their
patients. TPP clinicians expressed that the information in current
reports was insufficient and that links to external information
resources would be beneficial in their decision-making. PDMP clinicians liked the idea of providing ready access to electronic
resources with GS reports, with a preference for familiar and
trusted resources such as UpToDateÒ (www.uptodate.com). They
made specific suggestions for access to general information about
monogenic diabetes and the ability to print patient-targeted information. These preferences were incorporated in our choice of
information resources, organization of content, and incorporating
support for print and email capabilities into a proposed software
design. Other features incorporated into the GMA design included
proposed access to web-based resources using infobuttons and an
inbox of all reports available within the GMA.
4.2.2. Validated scenarios and proposed tasks for reviewing the
genomic medicine assistant design
Notification preferences informed the design of our scenarios.
Study participants indicated a need for improved mechanisms of
being notified of GS and laboratory results. EpicÒ Systems (Verona,
WI) alert and reminder capabilities in particular were discussed
during focus group sessions. Both TPP and PDMP recommended
considering alert messages in the EHR as a preferred mechanism
to notify and deliver GS reports. One suggestion brought up in
the TPP focus group specifically was to consider Epic InBasket messaging. EHR alert and reminder mechanisms (Epic Best Practice
Alert [BPA] and InBasket messages) were therefore incorporated
into scenarios as two proposed mechanisms for notifying clinicians
of GS reports. The BPA provides an interruptive form of clinical
decision support notification, while the InBasket provides a more
passive form of notification where new messages are indicated
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on a sidebar as the number of new messages that have been
received.
Scenarios are summarized in Table 2. Notification occurred
when a clinician opened the patient chart and methods of notification included Epic BPA and InBasket messages. Both contained
summary information about GS results and a link to view the
report in the GMA. In order to assess both types of notification
approaches, the first scenario presented to cardiology and
endocrinology clinicians used BPAs, while the second scenario contained an InBasket message.
Tasks outlined for the scenarios involved a user viewing an EHR
alert or reminder message, clicking on a link within that message
to access the GMA software, then viewing the GMA inbox containing the status of all ordered GS tests and reports. The user opens
the pre-selected GS report and is brought to a lab report Results
Tab that contains patient demographic data, the result, clinical significance, and recommendations. The Results Tab page also contains infobuttons that link to resources such as OMIMÒ [47],
GeneReviewsÒ [49], ClinVar [48], supporting literature, and a
patient resource. The user then clicks the Test Information tab,
which contains test limitations and other information. See Fig. 1
for an example of the Results Tab of the report.
4.3. Phase 2 results: clinician perceptions of tasks and screen mockups
Two main themes came out of the phase 2 focus group analysis.
First, there were differing opinions about proposed notification
methods. Second, there were user-specific needs for information
and consultation (Table 4).
For both of the EHR alert and reminder notification methods we
explored, participants expressed concerns about the frequency of
being notified of GS reports (Table 4). For BPAs specifically, the
potential for a high frequency of pop-up BPA alerts was a concern.
Participants agreed that the way the GMA Genetic Test Report tab
was structured to provide optional access to information resources
along with concise information summaries could help to overcome
issues with alert fatigue (or desensitization to frequent alerts) [38].
Which methods of notification were preferred also depended on
the scenario. For example, TPP clinician participants preferred both
methods of notification for the pharmacogenomic sequencing
panel report SCN5A result scenario, where as they preferred only
one method of notification for the CYP2C19 result scenario. Study
participants also noted that the preferred method of notification
might depend on familiarity with the scenario for using GS results.
User-specific needs for information and consultation became
evident from comments about clinicians’ familiarity with scenarios, comfort with using GS results and the GMA to make clinical
decisions, and preferences for referral processes (Table 4). Participants explained that confidence with using the GMA to make clinical decisions and their preferred referral processes may differ for a
non-specialized primary care provider (PCP) who may be unfamiliar with the GMA and/or GS results. Many participants agreed that
they would seek consultation from a genetics or pharmacogenetics
specialist after viewing the GS report.
4.4. Phase 2 results: design revision recommendations and perceptions
of usability
Study participants offered recommendations to improve the
navigation of the software to be more intuitive and the content
more easily and quickly understood (Table 5). These included
specific content improvements such as more clearly defining certain phenotypes. One important recommendation was to add a
resource to view evidence summaries regarding the clinical utility
of the data such as supporting clinical trials. Participants also perceived the GMA design to be usable with scores ranging from 72.5
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Fig. 1. Results tab features. This example shows a pharmacogenomic sequencing panel report. Note: this image was modified to illustrate the generalizable content sections
and features including tabs and infobuttons embedded in the demo. For screenshots of the Genomic Medicine Assistant demo see Appendix C.

to 95 out of 100 on the SUS Survey. These scores representing the
perceptions of our study participants, indicated an above average
usability score of the GMA.

5. Discussion
We have proposed a design for the Genomic Medicine Assistant
(GMA) software for generating a report from GS data and provide
resources to orient clinicians when viewing and interpreting results.

In phase 1 of our study, focus group participants offered insights into
the complex reporting process of genetic test results within two precision medicine programs (TPP and PDMP). Key areas of improvement were identified and considered when defining scenarios and
design features for the GMA. In phase 2 we assessed the GMA software design by conducting focus groups and task walkthroughs with
clinical end-users (physicians and nurse practitioners). Major findings we identified were the existence of (a) differing opinions
regarding preferred methods of notification and (b) user-specific
needs for information and consultation.
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Summary of scenarios.

Table 3
Proposed genomic medicine assistant software design features.

Lab report in the GMA

When opening a new encounter, the
healthcare provider is notified. . .

TPP Scenario 1: BPA notification of a
pharmacogenomic sequencing
panel report (CYP2C19)

. . .that their patient is a carrier of a
genetic variant that causes a
reduction in the ability to metabolize
clopidogrel. The message contains a
link to view the lab report in the GMA
. . .that their patient is a carrier of a
pathogenic variant in the SCN5A gene
relevant to Brugada Syndrome (an
incidental finding). The message
contains a link to view the lab report
in the GMA
. . .that their patient has a result
consistent with a diagnosis of a
genetic form of diabetes (MODY3)
caused by a mutation in HNF1A. The
message contains a link to view the
lab report in the GMA
. . .that their patient has a result
consistent with a diagnosis of a
genetic form of diabetes (MODY3)
caused by a mutation in HNF1A. The
message contains a link to view the
lab report in the GMA

TPP Scenario 2: InBasket notification
of a pharmacogenomic
sequencing panel report (SCN5A)

PDMP Scenario 1: BPA notification of
a monogenic diabetes sequencing
panel report (HNF1A)

PDMP Scenario 2: InBasket message
notification of a monogenic
diabetes sequencing panel report
(HNF1A)

Familiarity with a technology can assist with its integration into
everyday routines. To bolster clinician familiarity with information
provided in the GMA, clinician training and educational programs
may be effective. For example, one study piloted a ‘‘Genome
Report” containing whole genome sequencing results with nongeneticist physicians. They found that users viewed the report initially as daunting, but noted that as they became more familiar
with the report, they would be able to better manage subsequent
reports [39]. In our study, while familiarity with genetic test
results differed between clinicians involved in our two precision
medicine programs, there were common preferences for information. For example, regardless of previous experience and education
about GS described in our scenarios, many participants agreed that
they would likely seek consultation from a genetics or pharmacogenetics specialist after viewing the test report.
In addition, participants made several recommendations to
improve the proposed design of the GMA that can serve as design
principles for other pursuing similar efforts. Focus group participants reported a desire for information to support more in depth
understanding of GS results. Addressing this desire would need
to be considered with care given findings from others that using
too much bioinformatics or genetics jargon causes confusion
[21]. In addition, while actual navigation of the GMA software
interface could not be tested during our task walkthroughs, participants still proposed several areas to improve (Table 5).
Toward improving the likelihood of successful integration with
busy healthcare environments, we employed user-centered design
approaches to understand genetic testing workflow processes and
design preferences in order to understand points where technology
could help support those processes (see ‘‘Summary of Findings
from Analyzing Translational Pharmacogenetics Program Genetic
Testing Processes” and [30]) and to provide evidence for scenario
and software design choices. We found that the documentation
of GS results by multiple individuals, at different points in the testing process, and into independent locations can potentially lead to
the incorrect communication of a result. We therefore proposed
mechanisms for clinical decision support notification in our scenarios and proposed design features for documenting and viewing
GS reports with potential to mitigate some of those issues. Overall
the proposed scenarios (Table 2) and GMA design features (Table 3)

Deign feature
Screens
Inbox for test reports

Results tab

Test Information tab

Infobuttons
Gene (all scenarios)

Variant information (all scenarios)

Clinical significance (TPP scenario 2
and PDMP scenarios) [NOTE: this
button is not shown in Fig. 1]

Evidence (all scenarios)

Patient resource (all scenarios)

Description
This screen contains sortable patient
demographic information and the
test report status for quick selection
of reports
This screen contains patient
demographic information, test
indication, clinically relevant variant
results, results interpretation, and
recommendations
This screen contains information
about the test method and
limitations
This button opens a new window
that displays a gene resource (e.g.,
OMIM [47], a resource that provides
information about human genes and
genetic phenotypes, including supporting references to confirm genephenotype relationships)
This button opens a new window
that displays a gene variant resource
(e.g., ClinVar [48], a resource provides information about the variant
identified and the classification of the
variant)
This button opens a new window
that displays a resource to assist with
assessing clinical significance
resource (e.g., GeneReviews [49], a
resource provides information on
genetic diseases, focusing on clinically relevant and medically actionable information on the diagnosis,
management, and genetic counseling
of patients and families with specific
inherited conditions)
This button opens a new window
that lists citations or presents a
resource that synthesizes evidence to
support interpretations and
recommendations included in the
laboratory report
This button opens a new window
that displays a patient resource (e.g.,
Genetics Home Reference [50], a
resource that contains patientfriendly information about the gene
tested and disease-associated information)

were well accepted by our study participants. Preferences for notification by EHR alerts or reminders, however, may depend in part
on familiarity with GS results and urgency of the scenarios. For
example, for GS results that cardiology participants’ were less
familiar with, they preferred both BPA and InBasket notifications.
With CYP2C19 test results, for which they were more familiar,
the cardiology participants’ preferred InBasket notifications.
5.1. Limitations and future directions
We employed a user-centered design approach with the aim
of designing software that fits within current ways of working
(i.e., GS reporting processes that are similar to current laboratory
test delivery processes). There are some processes for GS reporting, however, that are distinct from other types of laboratory
tests such as the need to support mechanisms for continually
updating and improving genetic information. Our proposed
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Table 4
Phase 2 focus group excerpts that support major themes.
Theme

Excerpts

Differing opinions about
notification methods

‘‘I’m personally not a fan, that [the alert]
needs to be closed. [. . .] It stops what
you’re doing. It will do nothing but
aggravate providers” –Cardiology Fellow,
scenario 1
‘‘At the end of the day, [. . .] you’re going
through a ton of stuff and you just see
words and words and words, and words.
So you have that danger [of alert fatigue]
– I’m just going to breeze through that” –
Endocrinology Fellow, scenario 3
‘‘I wouldn’t want a box to pop up and stop
what you’re doing every time, but if the
person is on Plavix and has any test that
says they’re a poor metabolizer, they
should at least be noted on the side – like
a beacon, something that’s alerting you to
it without actually stopping what you’re
doing.” –Cardiology clinician, scenario 1
‘‘I would probably do both [methods of
notification]. I think the problem is this is
– this is potentially important
information...for the physician” –
Cardiology clinician, scenario 2

More information needed to
support understanding

‘‘At least having some background on that
[the content for clopidogrel poor
metabolizers] to get what it means [to
‘‘effectively metabolize”]. . ..That [the
common variants table] actually might be
a little bit vague for a provider who’s not
familiar with the test. . .It’s a small
change, but it may make a difference for a
lot of people that don’t understand the
test well. . ..It adds a degree of
uncertainty”–Cardiology clinician,
scenario 1
‘‘[. . .] what if in the variants table where
it says ‘clinical significance’, that column,
if you say ‘strong’ – [where] it says
‘pathogenic variant in gene associated
with MODY 3.’ What if you [also] put a
[classification of pathogenicity] or
something, just so you know how much
evidence backs it up.” –Endocrinology
clinician, scenario 3
‘‘[. . .] I would explain and say I don’t have
all the information. What I could tell you
is this. . . but I think we’re going to a
genetic – for a genetic consultation is
probably in the best interest.” –
Cardiology clinician, scenario 2
‘‘I think the reason to get a genetic person
involved is not so much just for the
patient but for family members as well,
because they’re going to have a lot of
other questions, regarding ‘what about
my children’. . . and I think that’s going to
be something that the genetics people
would have to sort out for you.”–
Cardiology clinician, scenario 2
‘‘I still think the PCPs wouldn’t be
comfortable to [make a clinical decision]
and that’s not surprising.” –
Endocrinology clinician, scenario 3
‘‘I mean, based on [the resources
provided] I would make a decision” –
Cardiology clinician, scenario 1

Differences in user’s decisions to
refer to specialist

Information needed within the
GMA may differ based on the
user

design feature to embed within GS reports links to external references and to continually updated genomic knowledge bases
such as ClinVar [40] would partially supports such mechanisms.
The scenarios we present in this work, however, were for the

delivery of results at one point in time, and do not explore potential changes to interpretations over time. One technology exploring mechanisms to provide updated interpretations of GS results
is GeneInsight, whose processes have been shown to greatly
improve the probability that users receive updated variant information [41]. Complementing that work would be research to better understand approaches to notify clinicians of updates to GS
findings and interpretations. There is potential to draw from
approaches in human factors engineering to analyze complex
work systems [42,43]. Approaches in contextual inquiry in particular may be used in order to design technology to support current work systems, or to design new ways of working that are
well supported by technology [44].
Another area for further exploration is scenarios for the return
of incidental findings unrelated to the indication for testing. This
work explored a scenario related to TPP project for the return of
a potential incidental finding upon ordering a pharmacogenomic
sequencing panel test for another purpose. Of note is that the scenario was highly exploratory and not based on current standards of
care. While others are exploring similar scenarios for returning GS
results with healthy individuals [9], current practice recommendations do not support GS for that purpose [45].
Some challenges brought up in phase 1 focus groups could not
be addressed directly in the design of the GMA. For example, a
clear need identified by participants was to improve the communication between laboratory systems and the EHR. Focus group participants also reported that some processes for notifying clinicians
of genetic test results do not notify the correct members of the care
team of an available test result in the TPP project [30]. In both
instances, solutions for these needs were beyond the scope of this
project. These are however broader implementation challenges
that will be addressed in the respective TPP and PDMP projects.
While our prototype can provide a starting point for exploring
scenarios for the reporting of multi-gene sequencing test results,
further research is needed to determine applicability to other scenarios and healthcare organizations. Future studies would benefit
from gathering feedback on multiple design concepts in order
identify the best solution for different environments. In addition,
usability studies where individuals are able to interact directly
with a prototype system may help users’ understanding of the
GMA application.
Furthermore, mechanisms to improve the communication
between laboratories and clinicians will be important. As we found
in our assessment of TPP genetic testing processes, laboratory processes for preparing the report are vital for the delivery of results.
The communication between clinicians and laboratories becomes
increasingly complex when GS is involved. Multiple factors now
play a part in this communication and should be considered when
building such a connection. These include informed consent, quality of testing, regulations of the testing laboratory, and most
importantly, interpretation of results [46]. While the GMA provides
a framework for delivering reports to clinicians, laboratory and
genetics professionals will continue to guide the development of
content for inclusion of GS reports and the identification of appropriate timing for delivering reports to clinicians.
In addition to these findings, study participants perceived the
GMA design to be usable and offered numerous design and content
recommendations to further improve its look and feel (Table 5).
Participant preferences for information resources and organization
of content from the first phase of the study were incorporated in
the prototype software design presented during the second phase.
Above average perceptions of usability were therefore unsurprising. Overall design principles resulting from our study can be
incorporated into software applications that support the delivery
of GS reports.
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Table 5
Phase 2 focus group design recommendations.
Timing and navigation recommendations
 Alert and reminder messages:
– Improve the visibility of the alert/reminder message link that would bring the user to the GMA software
– Provide with the alert/reminder message, an option to refer the patient to a genetics professional
 Throughout the software:
– Use mouse-overs to display definitions and spell-out acronyms
 Inbox:
– Provide support to archive reports, rather than to delete reports
– Provide support to indicate that a report has been reviewed
– Use color to indicate the status of a report (e.g., indicate that a final report is available to view with the color green)
– Include a ‘‘Result” column that shows a short description of the result
 Results tab:
– Make links to resources imbedded in the text more visible (e.g., UpToDateÒ [51] in the Monogenic Diabetes Sequencing Panel - Results Page (HNF1A), see Appendix C, Fig. C.5)
– Format the ‘‘Evidence” button bibliography to include the abstract of references
Content recommendations
 Alert and reminder messages:
– Include with generic drug names, the commercial names in parentheses
– Consider the order of treatment alternatives (e.g., Prasurgrel was recommended to be listed first in the TPP focus group)
– Consider including the same recommendation on the ‘‘Recommendations” section of the lab report as in the alert and reminder messages
& TPP example: Add contraindications for prescribing alternative medications included in the ‘‘Recommendations” section to the alert message
& PDMP example: Introduce link to UpToDateÒ [51] in the ‘‘Interpretation Summary” section earlier, possibly in the alert message
 Results tab
– Include with the ‘‘Evidence” button bibliography, citations from clinical studies
 Pharmacogenomic Sequencing Panel Report (CYP2C19):
– Bring table of common variants to Results tab [NOTE: this was incorporated into the demo report, see Appendix C, Fig. C.1]
– Define interpretation categorizes (e.g., It was recommended to include quantitative measures of decreased metabolism for poor metabolizers)
 Monogenic Diabetes Sequencing Panel (HNF1A):
– ‘‘Supporting literature” button should be called ‘‘Evidence” or ‘‘References” to minimize confusion about the type of information provided. [NOTE: this was
incorporated into the demo reports shown in Appendix C]

6. Conclusion
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